The DOI matches its Crossref record; 137 of the 137 references it cites were found in a registry or an index.
PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers
Open accessAbstract
The identification as cooperating targets of Proviral Integrations of Moloney virus in murine lymphomas suggested early on that PIM serine/threonine kinases play an important role in cancer biology. Whereas elevated levels of PIM1 and PIM2 were mostly found in hematologic malignancies and prostate cancer, increased PIM3 expression was observed in different solid tumors. PIM kinases are constitutively active and their activity supports in vitro and in vivo tumor cell growth and survival through modification of an increasing number of common as well as isoform-specific substrates including several cell cycle regulators and apoptosis mediators. PIM1 but not PIM2 seems also to mediate homing and migration of normal and malignant hematopoietic cells by regulating chemokine receptor surface expression. Knockdown experiments by RNA interference or dominant-negative acting mutants suggested that PIM kinases are important for maintenance of a transformed phenotype and therefore potential therapeutic targets. Determination of the protein structure facilitated identification of an increasing number of potent small molecule PIM kinase inhibitors with in vitro and in vivo anticancer activity. Ongoing efforts aim to identify isoform-specific PIM inhibitors that would not only help to dissect the kinase function but hopefully also provide targeted therapeutics. Here, we summarize the current knowledge about the role of PIM serine/threonine kinases for the pathogenesis and therapy of hematologic malignancies and solid cancers, and we highlight structural principles and recent progress on small molecule PIM kinase inhibitors that are on their way into first clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Nasser, M. W., Datta, J., Nuovo, G., Kutay, H., Motiwala, T., Majumder, S., Wang, B., Suster, S., Jacob, S. T., & Ghoshal, K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804788200 · Cited by 360
RetractedDelineation of prognostic biomarkers in prostate cancer
Dhanasekaran, S. M., Barrette, T. R., Ghosh, D., Shah, R., Varambally, S., Kurachi, K., Pienta, K. J., Rubin, M. A., & Chinnaiyan, A. M. (2001) · Nature · doi:10.1038/35090585 · Cited by 1,673
Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas
Pasqualucci, L., Neumeister, P., Goossens, T., Nanjangud, G., Chaganti, R. S. K., Küppers, R., & Dalla-Favera, R. (2001) · Nature · doi:10.1038/35085588 · Cited by 1,032
How do stem cells find their way home?
Lapidot, T., Dar, A., & Kollet, O. (2005) · Blood · doi:10.1182/blood-2005-04-1417 · Cited by 985
Myc-driven murine prostate cancer shares molecular features with human prostate tumors
Ellwood-Yen, K., Graeber, T. G., Wongvipat, J., Iruela-Arispe, M. L., Zhang, J., Matusik, R., Thomas, G. V., & Sawyers, C. L. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00197-1 · Cited by 816
Theo Cuypers, H., Selten, G., Quint, W., Zijlstra, M., Maandag, E. R., Boelens, W., van Wezenbeek, P., Melief, C., & Berns, A. (1984) · Cell · doi:10.1016/0092-8674(84)90309-x · Cited by 639
Hypoxia-Inducible mir-210 Regulates Normoxic Gene Expression Involved in Tumor Initiation
Huang, X., Ding, L., Bennewith, K. L., Tong, R. T., Welford, S. M., Ang, K. K., Story, M., Le, Q.-T., & Giaccia, A. J. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.09.006 · Cited by 617
Busillo, J. M., & Benovic, J. L. (2007) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2006.11.002 · Cited by 617
van Lohuizen, M., Verbeek, S., Krimpenfort, P., Domen, J., Saris, C., Radaszkiewicz, T., & Berns, A. (1989) · Cell · doi:10.1016/0092-8674(89)90589-8 · Cited by 496
Synergistic Roles for Pim-1 and c-Myc in STAT3-Mediated Cell Cycle Progression and Antiapoptosis
Shirogane, T., Fukada, T., Muller, J. M. M., Shima, D. T., Hibi, M., & Hirano, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80145-4 · Cited by 426
Cited by
For better or for worse: the role of Pim oncogenes in tumorigenesis
Nawijn, M. C., Alendar, A., & Berns, A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2986 · Cited by 481
Figueiredo, P., Lintinen, K., Kiriazis, A., Hynninen, V., Liu, Z., Bauleth-Ramos, T., Rahikkala, A., Correia, A., Kohout, T., Sarmento, B., et al. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2016.12.034 · Cited by 398
Administration, distribution, metabolism and elimination of polymer therapeutics
Markovsky, E., Baabur-Cohen, H., Eldar-Boock, A., Omer, L., Tiram, G., Ferber, S., Ofek, P., Polyak, D., Scomparin, A., & Satchi-Fainaro, R. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.021 · Cited by 313
Lucas, C. M., Harris, R. J., Giannoudis, A., Copland, M., Slupsky, J. R., & Clark, R. E. (2011) · Blood · doi:10.1182/blood-2010-08-304477 · Cited by 138
PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer
Luszczak, S., Kumar, C., Sathyadevan, V. K., Simpson, B. S., Gately, K. A., Whitaker, H. C., & Heavey, S. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0109-y · Cited by 102
Metadata
- Authors
- Brault, L., Gasser, C., Bracher, F., Huber, K., Knapp, S., & Schwaller, J.
- Venue
- Haematologica
- Published
- 2010-02-09
- Volume
- 95
- Issue
- 6
- Pages
- 1004-1015
- ISSN
- 0390-6078 (ISSN-L)
- 1592-8721
- OpenAlex
- W2099825600
- Cited by
- 368
- References
- 137
- FWCI
- 17.69
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. https://app.cochat.ai/papers/10.3324/haematol.2009.017079
- The paper
- Brault, L., Gasser, C., Bracher, F., Huber, K., Knapp, S., & Schwaller, J. (2010). PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica. https://doi.org/10.3324/haematol.2009.017079
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
